霉酚酸血药浓度监测的研究进展

Development of Therapeutic Drug Monitoring for Mycophenolic Acid's Plasma Concentration

免疫抑制剂的应用,显著地提高了器官或组织移植物的存活率,改善了患者的生存质量,对于器官或组织移植工作的开展起到了巨大的推动作用。目前,霉酚酸(MPA)类药物作为移植术后一线的抗增殖类免疫抑制剂,与临床上常用的免疫抑制剂:如环孢素A、他克莫司等药物均存在治疗窗狭窄、个体间和个体内变异性大的特点,临床上个体之间给药存在很大差异,往往需要根据血药浓度来调整用药剂量。本文就MPA药物血药浓度监测进展进行综述。

The application of immunosuppressor dramatically increased the survival rate of organ and tissue transplantation,improved the patients＇ life quality,and greatly promoted the organ and tissue transplant work.Fornow,mycophenolic acid（MPA）,as the first-line antiproliferative immunosuppressants after transplantation,has those characteristics,such as narrow therapeutic window and individual variation,as same as other common immunosuppressors,like Ciclosporin A,Tacrolimus,etc.Due to the great variation of drug administration in different patients,the dosage should be frequently adjusted according to the plasma concentration.This article would review the development of therapeutic drug monitoring（TDM）for MPA＇s plasma concentration.